Literature DB >> 23794094

A TP53 founder mutation, p.R337H, is associated with phyllodes breast tumors in Brazil.

Juliana Giacomazzi1, Patricia Koehler-Santos, Edenir Inez Palmero, Marcia S Graudenz, Luis Fernando Rivero, Eduardo Lima, Antonio Carlos Kruel Pütten, Pierre Hainaut, Suzi Alves Camey, Rodrigo Depieri Michelli, Cristovam Scapulatempo Neto, Mariana Fitarelli-Kiehl, Geraldo Geyer, Luise Meurer, Ana Geiger, Monica Blaya Azevedo, Vinicius Duval da Silva, Patricia Ashton-Prolla.   

Abstract

A few studies have reported phyllodes tumors (PT) of the breast with germline TP53 mutations. Given this potential association and the high frequency of the TP53 p.R337H in southern and southeastern Brazil, the aim of this study was to assess whether p.R337H occurs among women diagnosed with such rare tumors in this region. Benign, borderline, and malignant breast PT were retrieved from eight pathology laboratories, and DNA was extracted from tumor tissue to perform p.R337H analysis. Overall, 128 cases classified as benign, 7 as borderline, and 13 as malignant PT were included in the study. The TP53 p.R337H mutation was identified in tumor cells of eight (5.4 %) cases. Analysis of DNA from non-tumoral tissue was possible in two of these, and both were p.R337H carriers in the germline. In addition, haplotype analysis was done in these two p.R337H carriers showing the presence of the founder haplotype previously reported in Brazilian mutation-positive individuals. Mutation frequency was significantly higher among malignant (3 of 13; 23 %) compared to benign tumors (5 of 128; 3.4 %) (p = 0.004). Mean age at PT diagnosis was not significantly different between mutation carriers and non-carriers. However, when subgroups where analyzed, the difference in age at diagnosis of carriers versus non-carriers within the group of benign tumors reached borderline significance. Our findings reinforce previous evidence that TP53 mutations have an important role in the development of both benign and malignant PT of the breast.

Entities:  

Mesh:

Year:  2013        PMID: 23794094     DOI: 10.1007/s00428-013-1439-8

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  28 in total

1.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

2.  An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma.

Authors:  R C Ribeiro; F Sandrini; B Figueiredo; G P Zambetti; E Michalkiewicz; A R Lafferty; L DeLacerda; M Rabin; C Cadwell; G Sampaio; I Cat; C A Stratakis; R Sandrini
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

3.  An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors.

Authors:  A C Latronico; E M Pinto; S Domenice; M C Fragoso; R M Martin; M C Zerbini; A M Lucon; B B Mendonca
Journal:  J Clin Endocrinol Metab       Date:  2001-10       Impact factor: 5.958

4.  Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect.

Authors:  Sonia Garritano; Federica Gemignani; Edenir Inez Palmero; Magali Olivier; Ghyslaine Martel-Planche; Florence Le Calvez-Kelm; Laurence Brugiéres; Fernando Regla Vargas; Ricardo Renzo Brentani; Patricia Ashton-Prolla; Stefano Landi; Sean V Tavtigian; Pierre Hainaut; Maria Isabel W Achatz
Journal:  Hum Mutat       Date:  2010-02       Impact factor: 4.878

5.  A rare tumor and an ethical dilemma in a family with a germline TP53 mutation.

Authors:  Kamila Prochazkova; Lenka Foretova; Zdenek Sedlacek
Journal:  Cancer Genet Cytogenet       Date:  2008-01-01

6.  Phyllodes tumors.

Authors:  M D Rowell; R R Perry; J G Hsiu; S C Barranco
Journal:  Am J Surg       Date:  1993-03       Impact factor: 2.565

7.  Benign and malignant phyllodes tumors: mammographic and sonographic findings.

Authors:  L Liberman; E Bonaccio; D Hamele-Bena; A F Abramson; M A Cohen; D D Dershaw
Journal:  Radiology       Date:  1996-01       Impact factor: 11.105

8.  Two germ-line mutations affecting the same nucleotide at codon 257 of p53 gene, a rare site for mutations.

Authors:  S Mazoyer; P Lalle; C Moyret-Lalle; C Marçais; S Schraub; D Frappaz; H Sobol; M Ozturk
Journal:  Oncogene       Date:  1994-04       Impact factor: 9.867

9.  Fibroadenoma and cystosarcoma phyllodes of the male breast.

Authors:  Y Ansah-Boateng; F A Tavassoli
Journal:  Mod Pathol       Date:  1992-03       Impact factor: 7.842

10.  Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil.

Authors:  Gislaine Custodio; Guilherme R Taques; Bonald C Figueiredo; Elizabeth S Gugelmin; Mirna M Oliveira Figueiredo; Flora Watanabe; Roberto Pontarolo; Enzo Lalli; Luiz Fernando Bleggi Torres
Journal:  PLoS One       Date:  2011-03-22       Impact factor: 3.240

View more
  12 in total

1.  The breast cancer immunophenotype of TP53-p.R337H carriers is different from that observed among other pathogenic TP53 mutation carriers.

Authors:  Mariana Fitarelli-Kiehl; Juliana Giacomazzi; Patricia Santos-Silva; Marcia Silveira Graudenz; Edenir Inez Palmero; Rodrigo Augusto Depieri Michelli; Maria Isabel Achatz; Cynthia Aparecida Bueno de Toledo Osório; Victor Evangelista de Faria Ferraz; Clarissa Gondim Picanço; Patricia Ashton-Prolla
Journal:  Fam Cancer       Date:  2015-06       Impact factor: 2.375

Review 2.  Phyllodes tumours of the breast: a consensus review.

Authors:  Benjamin Y Tan; Geza Acs; Sophia K Apple; Sunil Badve; Ira J Bleiweiss; Edi Brogi; José P Calvo; David J Dabbs; Ian O Ellis; Vincenzo Eusebi; Gelareh Farshid; Stephen B Fox; Shu Ichihara; Sunil R Lakhani; Emad A Rakha; Jorge S Reis-Filho; Andrea L Richardson; Aysegul Sahin; Fernando C Schmitt; Stuart J Schnitt; Kalliopi P Siziopikou; Fernando A Soares; Gary M Tse; Anne Vincent-Salomon; Puay Hoon Tan
Journal:  Histopathology       Date:  2016-01       Impact factor: 5.087

3.  Contemporary Multi-Institutional Cohort of 550 Cases of Phyllodes Tumors (2007-2017) Demonstrates a Need for More Individualized Margin Guidelines.

Authors:  Laura H Rosenberger; Samantha M Thomas; Suniti N Nimbkar; Tina J Hieken; Kandice K Ludwig; Lisa K Jacobs; Megan E Miller; Kristalyn K Gallagher; Jasmine Wong; Heather B Neuman; Jennifer Tseng; Taryn E Hassinger; Tari A King; James W Jakub
Journal:  J Clin Oncol       Date:  2020-12-10       Impact factor: 44.544

4.  Prevalence and impact of founder mutations in hereditary breast cancer in Latin America.

Authors:  Patricia Ashton-Prolla; Fernando Regla Vargas
Journal:  Genet Mol Biol       Date:  2014-03       Impact factor: 1.771

5.  Comparison of multiple genotyping methods for the identification of the cancer predisposing founder mutation p.R337H in TP53.

Authors:  Mariana Fitarelli-Kiehl; Gabriel S Macedo; Rosane Paixão Schlatter; Patricia Koehler-Santos; Ursula da Silveira Matte; Patricia Ashton-Prolla; Juliana Giacomazzi
Journal:  Genet Mol Biol       Date:  2016-06-03       Impact factor: 1.771

Review 6.  Phyllodes Tumors: A Scoping Review of the Literature.

Authors:  Jessica Bogach; Saad Shakeel; Frances C Wright; Nicole J Look Hong
Journal:  Ann Surg Oncol       Date:  2021-07-22       Impact factor: 5.344

7.  Occurrence of Neuroblastoma among TP53 p.R337H Carriers.

Authors:  Ana Luiza Seidinger; Fernanda Paschoal Fortes; Maria José Mastellaro; Izilda Aparecida Cardinalli; Lilian Girotto Zambaldi; Simone Santos Aguiar; José Andrés Yunes
Journal:  PLoS One       Date:  2015-10-09       Impact factor: 3.240

8.  Ancestry of the Brazilian TP53 c.1010G>A (p.Arg337His, R337H) Founder Mutation: Clues from Haplotyping of Short Tandem Repeats on Chromosome 17p.

Authors:  Diego Davila Paskulin; Juliana Giacomazzi; Maria Isabel Achatz; Sandra Costa; Rui Manoel Reis; Pierre Hainaut; Sidney Emanuel Batista dos Santos; Patricia Ashton-Prolla
Journal:  PLoS One       Date:  2015-11-30       Impact factor: 3.240

9.  TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients.

Authors:  Eriza Cristina Hahn; Camila Matzenbacher Bittar; Fernanda Sales Luis Vianna; Cristina Brinckmann Oliveira Netto; Jorge Villanova Biazús; Rodrigo Cericatto; José Antônio Cavalheiro; Márcia Portela de Melo; Carlos Henrique Menke; Eliane Rabin; Sandra Leistner-Segal; Patricia Ashton-Prolla
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240

Review 10.  What 20 years of research has taught us about the TP53 p.R337H mutation.

Authors:  Emilia Modolo Pinto; Gerard P Zambetti
Journal:  Cancer       Date:  2020-08-17       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.